… Due to the plethora of such PSMA probes … those radiopharmaceuticals that have already
found widespread clinical application. In addition, recently introduced concepts such as PSMA-…

… in radiolabeled PSMA-targeting agents, mainly in diagnostic nuclear imaging. … target for
developing PSMA-specific radiopharmaceuticals for precise diagnosis, staging and treatment of …

… in targeted radionuclide therapy … PSMA ligand research and the therapeutic developments
are summarised, together with a future perspective on the enhancement of current therapeutic …

… use of PSMA PET in the imaging of patients with PCa, provide relevant data regarding the
therapeutic use and future potential of PSMA-targeted … of PSMA imaging and therapy in PCa. …

… Furthermore, PSMA was reported to be expressed in the … Most recently developed PSMA
targeting radiopharmaceuticals … to the extracellular domain of PSMA. This active binding site …

… that PSMA-targeting radiopharmaceuticals might be able to assess and predict treatment …
, one compared PSMA-targeted PET/CT in the setting of the treatment response assessment …

… and future role of radiopharmaceutical therapies in the … as docetaxel and cabazitaxel; targeted
agents such as the poly … pembrolizumab; as well as radiopharmaceuticals (which will be …

… PET-CT imaging and 177 Lu for therapy. In particular, … PSMA targeted agent is receiving
widespread interest and is one of the fastest growing radiopharmaceuticals for PET-CT imaging. …

… compare PSMA-targeting radiopharmaceuticals to … PSMA-targeting radiopharmaceuticals
for HCC is not inferior to the one observed in PET with choline-labeled radiopharmaceuticals, …

… a highly concentrated absorbed dose for therapy to the targeted tissues. A fundamental
consideration in developing radiometal-based targeted radiopharmaceuticals is the design and …